Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
The Prostate|November 27, 2024
Personalized Medicine: Leave no Patient Behind; Report From the 2024 Coffey-Holden Prostate Cancer Academy MeetingAndrea K Miyahira, Marina Sharifi, Lisa N Chesner, et al.
JCO Precision Oncology|May 17, 2023
MLH1 Loss in Primary Prostate CancerSanaz Nourmohammadi Abadchi, Laura A Sena, Emmanuel S Antonarakis, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2021
Mitochondrial metabolism is essential for invariant natural killer T cell development and functionXiufang Weng, Amrendra Kumar, Liang Cao, et al.
NPJ Precision Oncology|December 2, 2024
Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancerDena P Rhinehart, Jiaying Lai, David E Sanin, et al.
The Prostate|April 20, 2024
Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancerCatherine H Marshall, Lukasz P Gondek, Violet Daniels, et al.
Immunity|February 19, 2013
Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signalingLaura A Sena, Sha Li, Amit Jairaman, et al.
The Prostate|April 8, 2026
Castration Resistance Accelerates Prostate Cancer KineticsSheila Jonnatan, Luka Cavka, Angelo M De Marzo, et al.
Nature|January 11, 2019
Mitochondrial complex III is essential for suppressive function of regulatory T cellsSamuel E Weinberg, Benjamin D Singer, Elizabeth M Steinert, et al.
Molecular Cancer Research : MCR|May 1, 2026
HLA Class I Expression is Associated with Increased Immune Cell Density and PTEN Loss in Prostate CancerAdrianna Amaral, Thiago Vidotto, Juhyung Woo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2020
Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapyLaura A Sena, Hao Wang, Su J Lim ScM, et al.
Pageof 4